CADTH common drug review and formulary recommendation: Lurasidone (Latuda®) for schizophrenia

Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News The Canadian Drug Expert Committee (CDEC) has recommended that lurasidone not be listed for the acute treatment of schizophrenia. The Committee made this recommendation because there is insufficient evidence from randomised controlled trials (RCTs) to establish the comparative efficacy of lurasidone relative to other less costly antipsychotics for the acute treatment of schizophrenia.   Lurasidone is not currently licensed in the UK, although it has been filed for approval in the EU. A NICE evidence summary for new medicines for lurasidone is expected in April 2013.   Note: The Common Drug Review (CDR), at the Canadian Agency for Drugs and Technologies in Health (CADTH), is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs. CDR also provides formulary listing recommendations to Canada's publicly funded drug plans (except Quebec).
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news